Triple negative breast cancer

Common Name(s)

Triple negative breast cancer

Triple negative breast cancer (TNBC) describes any type of breast cancer that lacks three types of receptors that are often used for targeted treatments. These three types of receptors are estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2/neu). These receptors are involved in cell signaling and are found on affected cells in breast cancer that is not TNBC. There are different forms of TNBC, and about 10-20 percent of women who are diagnosed with breast cancer have a TNBC form.

Women who are younger in age, African American or Hispanic, and/or have mutations in the BRCA1 gene are more likely to have TNBC. TNBC often spreads more quickly than other types of breast cancer and presents a higher risk of coming back or recurring, especially in the first few years after treatment. After the first 3-5 years following treatment, the risk of recurrence of TNBC matches that of non-TNBC.

TNBC is diagnosed by taking a biopsy, or tissue sample, of the cancer. TNBC is less likely to respond to hormonal treatments but often does respond well to chemotherapy, radiation therapy, and surgery. If you have been diagnosed with TNBC, talk to your doctor about the most current treatment options. In addition, a genetic counselor can help discuss inheritance and risks to other family members. Support groups are a good source of information and can connect you with others who have been affected by breast cancer.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Triple negative breast cancer" for support, advocacy or research.

Logo
Bay Area Cancer Connections

We support people touched by breast and ovarian cancer by providing comprehensive, personalized services in an atmosphere of warmth and compassion.

Last Updated: 21 May 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Triple negative breast cancer" for support, advocacy or research.

Logo
Bay Area Cancer Connections

We support people touched by breast and ovarian cancer by providing comprehensive, personalized services in an atmosphere of warmth and compassion.

http://www.bcconnections.org

Last Updated: 21 May 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Triple negative breast cancer" returned 889 free, full-text research articles on human participants. First 3 results:

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.
 

Author(s): Margarite D Matossian, Steven Elliott, Van T Hoang, Hope E Burks, Theresa B Phamduy, Douglas B Chrisey, William J Zuercher, David H Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E Burow

Journal:

 

Triple negative breast cancers (TNBCs) have high recurrence and metastasis rates. Acquisition of a mesenchymal morphology and phenotype in addition to driving migration is a consequential process that promotes metastasis. Although some kinases are known to regulate a mesenchymal phenotype, ...

Last Updated: 3 Aug 2017

Go To URL
Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
 

Author(s): Masahito Kawazu, Shinya Kojima, Toshihide Ueno, Yasushi Totoki, Hiromi Nakamura, Akiko Kunita, Wei Qu, Jun Yoshimura, Manabu Soda, Takahiko Yasuda, Natsuko Hama, Mihoko Saito-Adachi, Kazuhito Sato, Shinji Kohsaka, Eirin Sai, Masako Ikemura, Shigeru Yamamoto, Tomoko Ogawa, Masashi Fukayama, Keiichiro Tada, Yasuyuki Seto, Shinichi Morishita, Shoichi Hazama, Tatsuhiro Shibata, Yoshihiro Yamashita, Hiroyuki Mano

Journal:

 

Triple-negative breast cancer (TNBC) cells do not express estrogen receptors, progesterone receptors, or human epidermal growth factor receptor 2. Currently, apart from poly ADP-ribose polymerase inhibitors, there are few effective therapeutic options for this type of cancer. Here, ...

Last Updated: 21 Jun 2017

Go To URL
Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.
 

Author(s): Angelo Gámez-Pozo, Lucía Trilla-Fuertes, Guillermo Prado-Vázquez, Cristina Chiva, Rocío López-Vacas, Paolo Nanni, Julia Berges-Soria, Jonas Grossmann, Mariana Díaz-Almirón, Eva Ciruelos, Eduard Sabidó, Enrique Espinosa, Juan Ángel Fresno Vara

Journal:

 

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and usually requires the administration of adjuvant chemotherapy after surgery but even with this treatment many patients still suffer from a relapse. The main objective of this study was to identify proteomics-based ...

Last Updated: 8 Jun 2017

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Triple negative breast cancer" returned 62 free, full-text review articles on human participants. First 3 results:

MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis.
 

Author(s): Lingshuang Lü, Xuhua Mao, Peiyi Shi, Biyu He, Kun Xu, Simin Zhang, Jianming Wang

Journal: Medicine (Baltimore). 2017 Jun;96(22):e7085.

 

Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by their aggressive nature and poor associated survival. MicroRNAs (miRs) have been found to play an important role in the occurrence and development of human cancers, but their role in the prognosis ...

Last Updated: 31 May 2017

Go To URL
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
 

Author(s): Giampaolo Bianchini, Justin M Balko, Ingrid A Mayer, Melinda E Sanders, Luca Gianni

Journal: Nat Rev Clin Oncol. 2016 Nov;13(11):674-690.

 

Chemotherapy is the primary established systemic treatment for patients with triple-negative breast cancer (TNBC) in both the early and advanced-stages of the disease. The lack of targeted therapies and the poor prognosis of patients with TNBC have fostered a major effort to discover ...

Last Updated: 27 Sep 2016

Go To URL
Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.
 

Author(s): Xuelei Ma, Xiaoshan Wang, Jingwen Huang, Yingtai Chen, Jing Zhang, Binglan Zhang, Changle Shi, Lei Liu

Journal:

 

Neoadjuvant therapy is administered to breast cancer patients as an induction process before surgery or radiotherapy to reduce tumor size. Human epidermal growth factor receptor-2 (HER-2) negative breast cancer lacks effective standard target therapy. Bevacizumab has a controversial ...

Last Updated: 1 Sep 2016

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer
 

Status: Available

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 6 Oct 2010

Go to URL
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
 

Status: Recruiting

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 19 Jul 2017

Go to URL
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
 

Status: Recruiting

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 22 May 2017

Go to URL